Cargando…

NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study

BACKGROUND: Although oral and intravenous forms of idronoxil have been well tolerated, the safety of NOX66, with idronoxil formulated as a rectal suppository, is not known. This Phase Ia/b clinical study (protocol No. NOX66-001A), known as Chemotherapy Enhancement Program-1, is the first to assess N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiknavelidze, Koba, Shavdia, Mikheil, Chikhladze, Nana, Abshilava, Lia, Messina, Marinella, Mautner, Gisela, Kelly, Graham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296080/ https://www.ncbi.nlm.nih.gov/pubmed/34306271 http://dx.doi.org/10.1016/j.curtheres.2021.100631

Ejemplares similares

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Methotrexate: an effective monotherapy for refractory generalized morphea
por: Platsidaki, Eftychia, et al.
Publicado: (2017)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020)

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
por: Patnaik, A, et al.
Publicado: (2014)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Nox
por: Hettche, Thomas, 1964-
Publicado: (1996)

3IA Conference (3IA’2011)
por: Plemenos, Dimitri, et al.
Publicado: (2012)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

A Case of Refractory Polymyositis Successfully Treated With Abatacept Monotherapy
por: ÇAĞLAYAN, Mehmet, et al.
Publicado: (2020)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis
por: Irie, Masahiro, et al.
Publicado: (2021)

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
por: Lim, Emerson A., et al.
Publicado: (2022)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
por: Birtle, A J, et al.
Publicado: (2004)

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2019)

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status
por: Igawa, Satoshi, et al.
Publicado: (2018)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Successful Treatment of Refractory Anemia in a Patient With Glycogen Storage Disease Type Ia Undergoing Hemodialysis
por: Sato, Hirotaka, et al.
Publicado: (2022)

Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy‐Refractory Testicular Tumors
por: Lian, Bijun, et al.
Publicado: (2019)

Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity
por: Muñoz, Mercedes, et al.
Publicado: (2019)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Primary Kaposi’s sarcoma of the heart in non-immunodeficient patient: case report and literature review
por: Makharoblidze, Eka, et al.
Publicado: (2015)

Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver
por: Isobe, Taichi, et al.
Publicado: (2009)

Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma
por: Deak-Mihaly, Dalma, et al.
Publicado: (2021)

PsicologÍa aplicada
por: Erismann, Th. (Theodor), 1883-
Publicado: (1925)

$\beta^-$ decay study of the $^{66}$Mn $-$ $^{66}$Fe $-$ $^{66}$Co $-$ $^{66}$Ni decay chain
por: Stryjczyk, M., et al.
Publicado: (2018)

How nephrotoxic is carboplatin?
por: Hardy, J. R., et al.
Publicado: (1990)

Carboplatin binding to histidine
por: Tanley, Simon W. M., et al.
Publicado: (2014)

NOX, NOX Who is There? The Contribution of NADPH Oxidase One to Beta Cell Dysfunction
por: Taylor-Fishwick, David A.
Publicado: (2013)

CRISPR/Cas9-mediated knockout of p22phox leads to loss of Nox1 and Nox4, but not Nox5 activity
por: Prior, Kim-Kristin, et al.
Publicado: (2016)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
por: Mascarenhas, Leo, et al.
Publicado: (2021)

Subpopulations of B cells distinguished by cell surface expression of Ia antigens. Correlation of Ia and idiotype during activation by cloned Ia-restricted T cells
Publicado: (1983)

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
por: Usmani, Saad Z., et al.
Publicado: (2018)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5aspffpapjt0obmmjdu593o9it